Back

Preliminary results from the Polish Infective Endocarditis Registry (POL-ENDO): time to change clinical approach?

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: New findings in infective endocarditis Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Jakub Orzech

National Institute of Cardiology, Warsaw (Poland)

7 More presentations in this session

Presentation thumbnail
Drug-use-associated infective endocarditis in Denmark
Mr J. Petersen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Postoperative heart valve infection, when and which bacteria: a nationwide cohort study
Mrs C. Holgersson (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Increased risk of infective endocarditis following transurethral resection of the prostate (TUR-P)
Ms A. Stahl (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
First in-human study of 64Cu-DOTATATE positron emission tomography/computed tomography(PET/CT) in infective endocarditis: a prospective head-to-head comparison with 18-FDG PET/CT
Doctor K. Hadji-Turdeghal (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Role of negative transthoracic echocardiography in excluding infective endocarditis
Doctor N. Cambise (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
New findings in infective endocarditis

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Women- do they need different guidelines? Sex differences in infective endocarditis: the POL-ENDO substudy (Polish Infective Endocarditis Registry)
thumbnail
Congress Presentation
Epidemiology and temporal trends of infective endocarditis between 2006 and 2018 at a tertiary referral center
thumbnail
Congress Presentation
Epidemiological profile and mortality of infective endocarditis over the past decade: a systematic review and meta-analysis of 133 studies comprising 132,355 cases

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources